FrancophonIA/ELRC3.0 huggingface dataset:
English: Cordinate plus 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Cordinate plus 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (14.9/11.3 mmHg) compared to hydrochlorothiazide 12.5 mg (5.2/2.9 mmHg) and hydrochlorothiazide 25 mg
Estonian: Topeltpimedas, randomiseeritud, aktiivse võrdlusravimiga kontrollitud uuringus patsientidel, kellel ei saavutatud 12,5 mg hüdroklorotiasiidi kasutamisel piisavat vererõhu langust, täheldati oluliselt suuremat keskmist süstoolse/diastoolse vererõhu langust valsartaani/hüdroklorotiasiidi 80/12,5 mg kombinatsiooni kasutamisel (14,9/11,3 mmHg) võrreldes 12,5 mg hüdroklorotiasiidi (5,2/2,9 mmHg) ja 25 mg hüdroklorotiasiidiga (6,8/5,7 mmHg).
English: Diovan Comp and associated names (see Annex I) 80 mg/12.5 mg film-coated tablets Diovan Comp and associated names (see Annex I) 160 mg/12.5 mg film-coated tablets Diovan Comp and associated names (see Annex I) 160 mg/25 mg film-coated tablets Diovan Comp and associated names (see Annex I) 320 mg/12.5 mg film-coated tablets Diovan Comp and associated names (see Annex I) 320 mg/25 mg film-coated tablets Valsartan/hydrochlorothiazide
Estonian: Diovan Comp ja sarnased nimetused (vt Lisa I) 80 mg/12,5 mg õhukese polümeerikattega tabletid Diovan Comp ja sarnased nimetused (vt Lisa I) 160 mg/12,5 mg õhukese polümeerikattega tabletid Diovan Comp ja sarnased nimetused (vt Lisa I) 160 mg/25 mg õhukese polümeerikattega tabletid Diovan Comp ja sarnased nimetused (vt Lisa I) 320 mg/12,5 mg õhukese polümeerikattega tabletid Diovan Comp ja sarnased nimetused (vt Lisa I) 320 mg/25 mg õhukese polümeerikattega tabletid Valsartaan/hüdroklorotiasiid
English: Each tablet contains 320 mg of valsartan and 12.5 mg of hydrochlorothiazide.
Estonian: Iga tablett sisaldab 320 mg valsartaani ja 12,5 mg hüdroklorotiasiidi.
English: Cordinate plus 80/12.5 mg 80 mg / 12.5 mg film-coated tablets oral
Estonian: Cordinate plus 80/12.5 mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Dalzad (320+12.5) mg 320 mg / 12,5 mg film-coated tablets oral
Estonian: Co-Dalzad (320+12.5) mg 320 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazide, including hydrochlorothiazide.
Estonian: Liitiumi kasutamisel koos AKE inhibiitorite ja tiasiidiga (sh hüdrokloritiasiidi) on esinenud seerumi liitiumikontsentratsioonide pöördumatut tõusu ja toksilisust.
English: These doses in rat, respectively, represent 0.9 and 3.5-times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis.
Estonian: Rottidel kasutatud annused on vastavalt 0,9 ja 3,5 korda suuremad valsartaani ja hüdroklorotiasiidi maksimaalsest inimesele soovitatavast annusest mg/m2 baasil.
English: • low level of potassium in the blood (sometimes with muscle weakness, muscle spasms,
Estonian: • madal kaaliumisisaldus veres (mõnikord koos lihasnõrkuse, lihasspasmide, südame rütmihäiretega)
English: Co- Novacard 80/12.5 mg 80 mg / 12.5 mg film-coated tablets oral
Estonian: Co- Novacard 80/12.5 mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: The kinetics of valsartan are not markedly affected by the co-administration of hydrochlorothiazide.
Estonian: Hüdroklorotiasiidi samaaegne manustamine ei mõjuta märkimisväärselt valsartaani kineetikat.
English: Co- Novacard 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Co- Novacard 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Dalzad (160+25) mg 160 mg / 25 mg film-coated tablets oral
Estonian: Co-Dalzad (160+25) mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Hypersenstivity reactions
Estonian: Ülitundlikkusreaktsioonid
English: Each tablet contains 160 mg of valsartan and 12.5 mg of hydrochlorothiazide.
Estonian: Iga tablett sisaldab 160 mg valsartaani ja 12,5 mg hüdroklorotiasiidi.
English: Slovenia Novartis Pharma GmbH Roonstrasse 25
Estonian: Sloveenia Novartis Pharma GmbH Roonstrasse 25
English: Diovan Comp 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Diovan Comp 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours.
Estonian: Maksimaalseid kontsentratsioone vereplasmas täheldati 2-4 tunni jooksul pärast valsartaani suukaudset manustamist ainsa ravimina.
English: • dizziness
Estonian: • unehäired
English: Co-Dalzad (320+25) mg 320 mg / 25 mg film-coated tablets oral
Estonian: Co-Dalzad (320+25) mg 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Cordinate plus 320/12.5 mg 320 mg / 12.5 mg film-coated tablets oral
Estonian: Cordinate plus 320/12.5 mg 320 mg / 12,5 mg õhukese polümeerikattega tabletid
English: • irregular heart beat
Estonian: • ebakorrapärane südametegevus
English: Co- Novacard 160/25 mg 160 mg / 25 mg film-coated tablets oral
Estonian: Co- Novacard 160/25 mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: In addition, a significantly greater percentage of patients responded (BP <140/90 mmHg or SBP reduction ≥20 mmHg or DBP reduction ≥10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).
Estonian: Lisaks saavutas ravivastuse (vererõhk <140/90 mmHg või süstoolse vererõhu langus ≥20 mmHg või diastoolse vererõhu langus ≥10 mmHg) oluliselt suurem protsent patsiente 160/12,5 mg valsartaani/hüdroklorotiasiidi (50%) kui 25 mg hüdroklorotiasiidi (25%) kasutamisel.
English: Each tablet contains 80 mg of valsartan and 12.5 mg of hydrochlorothiazide.
Estonian: Iga tablett sisaldab 80 mg valsartaani ja 12,5 mg hüdroklorotiasiidi.
English: Adverse reactions known to occur with each component given individually but which have not been seen in clinical trials may occur during treatment with valsartan/hydrochlorothiazide.
Estonian: Ravi ajal valsartaani/ hüdroklorotiasiidiga võivad tekkida kõrvaltoimed, mida teadaolevalt esineb kumbagi komponendi eraldi kasutamisel, kuid mida ei ole täheldatud kliinilistes uuringutes.
English: Nervous system disorders Rare
Estonian: Närvisüsteemi häired Harv
English: In addition, a significantly greater percentage of patients responded (diastolic BP <90 mmHg or reduction ≥10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (60%) compared to hydrochlorothiazide 12.5 mg (25%) and hydrochlorothiazide 25 mg (27%).
Estonian: <90 mmHg või langus ≥10 mmHg) oluliselt suurem protsent patsiente 80/12,5 mg valsartaani/hüdroklorotiasiidi (60%) kui 12,5 mg hüdroklorotiasiidi (25%) ja 25 mg hüdroklorotiasiidi (27%) kasutamisel.
English: Lactation
Estonian: Neerupuudulikkus
English: Cotareg 160mg/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Cotareg 160mg/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: • facial rash associated with joint pain
Estonian: • lööve näol, millega kaasneb liigesvalu
English: Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by amantadine.
Estonian: Amantadiin Tiasiidid (sh hüdroklorotiasiid) võivad suurendada amantadiini kõrvatoimete riski.
English: Diovan Comp 320/12.5 mg 320 mg / 12.5 mg film-coated tablets oral
Estonian: Diovan Comp 320/12.5 mg 320 mg / 12,5 mg õhukese polümeerikattega tabletid
English: • low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
Estonian: • madal vereliistakute arv (mõnikord koos veritsuse ja nahaaluste verevalumite tekkega)
English: Romania Novartis Pharma GmbH Roonstrasse 25
Estonian: Rumeenia Novartis Pharma GmbH Roonstrasse 25
English: Luxembourg Novartis Pharma GmbH Roonstrasse 25
Estonian: Luksemburg Novartis Pharma GmbH Roonstrasse 25
English: Co-Diovan (160 + 12.5 mg) 160 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovan (160 + 12.5 mg) 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: CO-DIOVAN 320 mg/12,5 mg FILMCOATED TABLETS
Estonian: CO-DIOVAN 320 MG/12,5 MG FILM-COATED TABLETS
English: Co-Diovan (320 + 12.5 mg) 320 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovan (320 + 12.5 mg) 320 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Frequency of adverse reactions with valsartan/hydrochlorothiazide
Estonian: Valsartaan/hüdroklorotiasiidi kõrvaltoimete esinemissagedus
English: Co-Diovan (80+12,5) mg 80 mg / 12,5 mg film-coated tablets oral
Estonian: Co-Diovan (80+12,5) mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Diovan (160+12,5) mg 160 mg / 12,5 mg film-coated tablets oral
Estonian: Co-Diovan (160+12,5) mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Diovan (80 + 12.5 mg) 80 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovan (80 + 12.5 mg) 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Cotareg 160mg/25 mg 160 mg / 25 mg film-coated tablets oral
Estonian: Cotareg 160mg/25 mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Impaired renal function
Estonian: Neerufunktsiooni häired
English: Co-Diovan (320+12,5) mg 320 mg / 12,5 mg film-coated tablets oral
Estonian: Co-Diovan (320+12,5) mg 320 mg / 12,5 mg õhukese polümeerikattega tabletid
English: These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis.
Estonian: Küünisahvidel kasutatud annused on vastavalt 0,9 ja 3,5 korda suuremad valsartaani ja hüdroklorotiasiidi maksimaalsest inimesele soovitatavast annusest mg/m2 baasil.
English: CORIXIL 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: CORIXIL 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: The treatment with a thiazide may influence the glucose tolerance.
Estonian: Diabeedivastased ravimid (suukaudsed preparaadid ja insuliin) Tiasiidravi võib mõjutada glükoositaluvust.
English: Co-Diovan (320 + 25 mg) 320 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan (320 + 25 mg) 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Co-Diovan (160 + 25 mg) 160 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan (160 + 25 mg) 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Germany Novartis Pharma GmbH Roonstrasse 25
Estonian: Saksamaa Novartis Pharma GmbH Roonstrasse 25
English: Cotareg 80mg/12.5 mg 80 mg / 12.5 mg film-coated tablets oral
Estonian: Cotareg 80mg/12.5 mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Diovan (160+25) mg 160 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan (160+25) mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 160mg/25 160 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 160mg/25 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 160mg/25 mg 160 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 160mg/25 mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 80mg/12.5 mg80 mg / 12.5 mg film-coated tablets oral
Estonian: Diovan Comp 80mg/12.5 mg80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Cholestyramine and cholestipol resins
Estonian: Paresteesia, minestus
English: Co-Diovan (320+25) mg 320 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan (320+25) mg 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 80 mg/12.5 mg80 mg / 12.5 mg film-coated tablets oral
Estonian: Diovan Comp 80 mg/12.5 mg80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Diovan Comp 160 mg/25 mg160 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 160 mg/25 mg160 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 320mg/25 mg 320 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 320mg/25 mg 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Co-Diovane 80/12,5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovane 80/12,5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Diovan 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovan 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Co-Diovan forte 160/25 mg 160 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan forte 160/25 mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 80/12.5 mg 80 mg / 12.5 mg film-coated tablets oral
Estonian: Diovan Comp 80/12.5 mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Diovan Comp 320 mg/25 mg320 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 320 mg/25 mg320 mg / 25 mg õhukese polümeerikattega tabletid
English: Myalgia
Estonian: Metüüldopa
English: Diovan Comp 160/25 mg 160 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 160/25 mg 160 mg / 25 mg õhukese polümeerikattega tabletid
English: • sleep disturbances
Estonian: • neerutalitluse häire
English: Co-Diovane 160/12.5 mg 160 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovane 160/12.5 mg 160 mg / 12,5 mg õhukese polümeerikattega tabletid
English: Special populations
Estonian: Muud ainevahetushäired
English: Vasculitis
Estonian: Pearinglus
English: Co-Diovan forte 320/25 mg 320 mg / 25 mg film-coated tablets oral
Estonian: Co-Diovan forte 320/25 mg 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Diovan Comp 320/25 mg 320 mg / 25 mg film-coated tablets oral
Estonian: Diovan Comp 320/25 mg 320 mg / 25 mg õhukese polümeerikattega tabletid
English: Co-Diovan 80/12.5 mg 80 mg / 12.5 mg film-coated tablets oral
Estonian: Co-Diovan 80/12.5 mg 80 mg / 12,5 mg õhukese polümeerikattega tabletid
English:  This medicine has been prescribed for you only.
Estonian: Ravim on välja kirjutatud üksnes teile.
English: Therefore, this combination is not recommended (see section 4.4).
Estonian: Seetõttu taolist kombinatsinooni ei soovitata (vt lõik 4.4).
English: Date of latest renewal: 19 January 2012
Estonian: Müügiloa viimase uuendamise kuupäev: 19. jaanuar 2012
English: The safety and efficacy of Irbesartan Zentiva in children aged 0 to 18 has not been established.
Estonian: Lapsed: Irbesartan Zentiva ohutus ja efektiivsus lastel vanuses 0 kuni 18 aastat ei ole veel tõestatud.
English: Other medicines and Irbesartan Zentiva
Estonian: Muud ravimid ja Irbesartan Zentiva
English: See also information under the heading “Do not take Irbesartan Zentiva”.
Estonian: Vt ka teavet lõigus „Ärge võtke Irbesartan Zentiva't”.
English: If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicinal product.
Estonian: Kui arst on teile öelnud, et teil on mõnede suhkrute (nt laktoosi) talumatus, konsulteerige enne selle ravimi kasutamist arstiga.
English: Irbesartan Zentiva should not be given to children under 18 years of age.
Estonian: Irbesartan Zentiva't ei tohi anda lastele ja noorukitele vanuses kuni 18 aastat.
English: However, no proper explanation for these findings in women has been identified.
Estonian: Nende leidudemehhanismi naistel ei osata seletada.
English: It is important that you continue to take Irbesartan Zentiva until your doctor tells you otherwise.
Estonian: Oluline on kasutada Irbesartan Zentiva nii kaua kuni arst ei ole otsustanud teisiti.
English: How to store Irbesartan Zentiva Contents of the pack and other information
Estonian: Kuidas Irbesartan Zentiva't säilitada Pakendi sisu ja muu teave
English: Therefore, the use of Irbesartan Zentiva is not recommended.
Estonian: Seetõttu ei ole Irbesartan Zentiva kasutamine soovitatav.
English: What Irbesartan Zentiva is and what it is used for What you need to know before you take Irbesartan Zentiva How to take Irbesartan Zentiva Possible side effects
Estonian: Mis ravim on Irbesartan Zentiva ja milleks seda kasutatakse Mida on vaja teada enne Irbesartan Zentiva võtmist Kuidas Irbesartan Zentiva't kasutada Võimalikud kõrvaltoimed
English: The efficacy of Irbesartan Zentiva is not influenced by age or gender.
Estonian: Irbesartan Zentiva efektiivsust ei mõjuta vanus või sugu.
English: Please see section 2 “Irbesartan Zentiva contains lactose”.
Estonian: Vt lõik 2, „Irbesartan Zentiva sisaldab laktoosi“.
English: You can take Irbesartan Zentiva with or without food.
Estonian: Irbesartan Zentiva võib võtta kas koos toiduga või ilma.
English: If you take more Irbesartan Zentiva than you should If you accidentally take too many tablets, contact your doctor immediately.
Estonian: Kui te võtate Irbesartan Zentiva't rohkem kui ette nähtud Kui võtsite kogemata liiga palju tablette, siis peate sellest koheselt arstile teatama.
English: IDNT was a double blind, controlled, morbidity and mortality trial comparing Irbesartan Zentiva, amlodipine and placebo.
Estonian: IDNT oli topeltpime, kontrollgrupiga, haigestumuse ja suremuse uuring, kus võrreldi Irbesartan Zentiva't, amlodipiini ja platseebot.
English: If you get any of these symptoms or get short of breath, stop taking Irbesartan Zentiva and contact your doctor immediately.
Estonian: Kui arvate, et teil on tekkinud selline kõrvaltoime või tekib hingeldus, lõpetage Irbesartan Zentiva võtmine ja pöörduge koheselt arsti poole.
English: The study examined the long-term effects (2 years) of Irbesartan Zentiva on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/day, and an increase in UAER of at least 30% from baseline).
Estonian: Uuring käsitles Irbesartan Zentiva pikaajalist (2 aastat) toimet kliinilise (manifesteerunud) proteinuuria (uriini albumiini ekskretsiooni määr (urinary albumin excretion rate, UAER) > 300 mg/ööpäevas ja UAER suurenemine vähemalt 30% algväärtusest) tekkele.
English: Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Irbesartan Zentiva (see section 4.4).
Estonian: Eelnev ravi diureetikumi suurte annustega võib põhjustada vedeliku mahu vähenemist ja hüpotensiooni ohtu Irbesartan Zentiva'ga ravi alustamisel (vt lõik 4.4).
English: Irbesartan Zentiva belongs to a group of medicines known as angiotensin-II receptor antagonists.
Estonian: Irbesartan Zentiva kuulub ravimite gruppi, mida tuntakse angiotensiin-II retseptori antagonistidena.
English: Irbesartan Zentiva is indicated in adults for the treatment of essential hypertension.
Estonian: Irbesartan Zentiva on näidustatud essentsiaalse hüpertensiooni raviks täiskasvanutel.
English: What you need to know before you take Irbesartan Zentiva
Estonian: Mida on vaja teada enne Irbesartan Zentiva võtmist
English: While this is not documented with Irbesartan Zentiva, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Estonian: Kuigi seda ei ole dokumenteeritud Irbesartan Zentiva puhul, tuleb arvestada angiotensiin-II retseptorite antagonistide samasuguse toimega.
English: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist.
Estonian: Toimemehhanism: Irbesartaan on tugevatoimeline, suukaudselt aktiivne, selektiivne angiotensiin-II retseptori (tüüp AT1) antagonist.
English: Regression to normoalbuminuria (< 30 mg/day) was more frequent in the Irbesartan Zentiva 300 mg group (34%) than in the placebo group (21%).
Estonian: Normoalbuminuuria (< 30 mg/ööpäevas) tekkis sagedamini Irbesartan Zentiva 300 mg grupis (34%) kui platseebogrupis (21%).
English: Irbesartan Zentiva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Estonian: Irbesartan Zentiva ei soovitata rinnapiimaga toitvatele emadele ning arst võib soovitada teile mõne muu ravimi kui soovite last rinnapiimaga toita, eriti kui tegemist on vastsündinu või enneaegse imikuga.
English: Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Estonian: Ligikaudu 33% irbesartaani grupi patsientidest esines esmane liit-tulemusnäitaja, võrreldes 39% ja 41% platseebo ja amlodipiini grupis suhtelise riski alanemine 20% vs platseebo (p = 0,024) ja suhtelise riski alanemine 23% võrreldes amlodipiiniga (p = 0,006).
English: Some undesirable effects have been reported since marketing of Irbesartan Zentiva.
Estonian: Mõnedest kõrvaltoimetest on teatatud Irbesartan Zentiva turustamisjärgselt.
English: o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
Estonian: AKE-inhibiitor (näiteks enalapriil, lisinopriil, ramipriil), eriti kui teil on suhkurtõvest tingitud neeruprobleemid; aliskireen.
English: Such conditions should be corrected before the administration of Irbesartan Zentiva.
Estonian: Sellised seisundid tuleb korrigeerida enne ravi alustamist Irbesartan Zentiva'ga.
English: Irbesartan Zentiva is for oral use.
Estonian: Irbesartan Zentiva on suukaudseks kasutamiseks.
English: What Irbesartan Zentiva is and what it is used for
Estonian: Mis ravim on Irbesartan Zentiva ja milleks seda kasutatakse
English: Lactose: patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Estonian: Harvaesineva päriliku galaktoositalumatuse, täieliku laktaasipuudulikkuse või glükoosi-galaktoosi imendumishäirega patsiendid ei tohi seda ravimit kasutada.
English: Irbesartan Zentiva prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Estonian: Irbesartan Zentiva hoiab ära angiotensiin-II seondumise nende retseptoritega, põhjustades veresoonte lõõgastumise ja alandab vererõhku.
English: If you forget to take Irbesartan Zentiva
Estonian: Kui te unustate Irbesartan Zentiva't võtta
English: Marketing Authorisation Holder: Zentiva k.s.
Estonian: Müügiloa hoidja: Zentiva k.s.
English: Because no information is available regarding the use of Irbesartan Zentiva during breast-feeding, Irbesartan Zentiva is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Estonian: Kuivõrd andmeid Irbesartan Zentiva kasutamisest imetamise ajal ei ole, ei ole soovitatav Irbesartan Zentiva siis kasutada ning eelistada tuleks ravimit, mille ohutusprofiil lubab kasutamist imetamise ajal, eriti kui rinnapiimaga toidetakse vastsündinut või enneaegset imikut.
English: Do not take Irbesartan Zentiva  if you are allergic to irbesartan or any other ingredients of this medicine (listed in section 6)  if you are more than 3 months pregnant.
Estonian: Ärge võtke Irbesartan Zentiva't kui olete irbesartaani või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline,  kui rasedus on kestnud üle 3 kuu (ka raseduse algul on parem vältida Irbesartan Zentiva kasutamist - vt lõiku „Rasedus“).
English: Irbesartan Zentiva is unlikely to affect your ability to drive or use machines.
Estonian: Irbesartan Zentiva ei mõjuta tõenäoliselt autojuhtimise ja masinate käsitsemise võimet.
English: In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Irbesartan Zentiva (see section 4.5).
Estonian: Diureetikumi, nt hüdroklorotiasiidi lisamine on näidanud aditiivset toimet Irbesartan Zentiva'ga (vt lõik 4.5).
English: Irbesartan Zentiva with food and drink Irbesartan Zentiva can be taken with or without food.
Estonian: Irbesartan Zentiva koos toidu ja joogiga Irbesartan Zentiva't võib kasutada söögiajast sõltumatult.
English: Excipients: also contains lactose monohydrate.
Estonian: Abiained: sisaldab lisaks laktoosmonohüdraati.
English: Irbesartan Zentiva contains lactose.
Estonian: Irbesartan Zentiva sisaldab laktoosi.